Şahinoğlu Ece, Boyacı Haşim, Kır Hale Maral, Ilgazlı Ahmet Hamdi, Başyiğit İlknur, Argun Barış Serap
Department of Immunology and Allergic Disease, Ankara University Faculty of Medicine, Ankara, Türkiye.
Department of Pulmonary Diseases, Kocaeli University Faculty of Medicine, Kocaeli, Türkiye.
Thorac Res Pract. 2025 Aug 15;26(5):217-223. doi: 10.4274/ThoracResPract.2025.2025-1-2. Epub 2025 Jun 3.
Serum chitotriosidase (CHIT) is a promising biomarker that has shown high specificity and sensitivity in patients with sarcoidosis. Our study aimed to evaluate the CHIT enzyme concerning the activity, prognosis, and treatment decision of sarcoidosis.
The patients with the following characteristics were included in our single-center study as long as they agreed to participate. These patients were newly or previously diagnosed with sarcoidosis according to American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and Other Granulomatous Disorders and consulted the outpatient clinic of chest diseases in our university hospital between August 2020 and April 2021. The patients with sarcoidosis were categorized into 3 groups: 1) diagnosed as sarcoidosis but not having the treatment indication; 2) previouslytreated or currently receiving treatment; and 3) newly diagnosed and having a treatment indication.
A total of 126 sarcoidosis patients and 43 healthy volunteers were included. The median value of serum CHIT enzyme levels in patients with sarcoidosis was determined to be 9.8 ng/mL, while it was 5.1 ng/mL in the control group. It was determined that the serum CHIT levels were notably higher in patients with sarcoidosis ( = 0.000). In the serum CHIT levels of the newly-treated patient, a significant reduction was observed after the 6-month treatment ( = 0.008), in comparison with these levels noted at the time of diagnosis.
Our study demonstrated that the serum CHIT has a high sensitivity and high specificity in the diagnosis of sarcoidosis and a reduction in the level of that enzyme occurs upon treatment.
血清壳三糖苷酶（CHIT）是一种很有前景的生物标志物，在结节病患者中显示出高特异性和敏感性。我们的研究旨在评估CHIT酶在结节病的活性、预后及治疗决策方面的情况。
只要符合以下特征且同意参与的患者均纳入我们的单中心研究。这些患者根据美国胸科学会/欧洲呼吸学会/结节病及其他肉芽肿性疾病世界协会标准，于2020年8月至2021年4月期间在我校医院胸科门诊新诊断或既往诊断为结节病。结节病患者分为3组：1）诊断为结节病但无治疗指征；2）既往接受过治疗或正在接受治疗；3）新诊断且有治疗指征。
共纳入126例结节病患者和43名健康志愿者。结节病患者血清CHIT酶水平的中位数为9.8 ng/mL，而对照组为5.1 ng/mL。确定结节病患者血清CHIT水平显著更高（P = 0.000）。新治疗患者的血清CHIT水平在治疗6个月后与诊断时相比有显著降低（P = 0.008）。
我们的研究表明，血清CHIT在结节病诊断中具有高敏感性和高特异性，且治疗后该酶水平会降低。
